Is MOTs-c legal? the comprehensive answer.

Current US FDA status

MOTs-c has no FDA-approved drug application. No pharmaceutical company has taken MOTs-c through the New Drug Application (NDA) process, and no MOTs-c product has been approved for any indication. As a peptide compound, MOTs-c also does not qualify under the Dietary Supplement Health and Education Act (DSHEA) of 1994, so it is not a permitted dietary supplement ingredient.

Historically, MOTs-c was placed on the FDA’s Category 2 list of bulk drug substances. Category 2 is the FDA’s designation for substances that licensed compounding pharmacies are not permitted to use. Inclusion on Category 2 reflects the FDA’s view that the substance, given the available evidence, identity characterization, and safety data, should not be compounded under the federal compounding framework.

On April 15, 2026, the FDA published an update to the bulk drug substance lists that removed MOTs-c, alongside a cohort of related peptides, from the explicit Category 2 list. Critically, the same update did not place MOTs-c on Category 1, which is the affirmative permission for compounding.

The result is a regulatory ambiguity. MOTs-c is not on the explicit prohibition list, and it is not on the explicit permission list. It is in a pending-review state ahead of evaluation by the Pharmacy Compounding Advisory Committee (PCAC). Some 503A compounding pharmacies have interpreted the removal from Category 2 as lifting the prior prohibition. Others, more conservatively, are waiting for an explicit Category 1 placement before compounding the substance. Both interpretations exist in the marketplace, and the legal posture is genuinely ambiguous.

PepScribe’s pharmacy standard is 503A-only, and our position on MOTs-c is consultation-first. MOTs-c is not a peptide-direct product on this platform. A licensed clinician evaluates the patient’s goals, history, and current medications, then decides whether any peptide therapy is appropriate, and which peptide that should be, within the formulary that is available under current US rules.

The endogenous-vs-exogenous distinction

One of the most common arguments for regulatory leniency around MOTs-c runs roughly as follows: the body produces MOTs-c on its own, so administering more of it should not require the same regulatory machinery as a synthetic novel drug. The argument is appealing and partially correct, but it does not do the legal or pharmacological work that proponents tend to assume.

A useful comparison is insulin. Insulin is endogenous in nearly everyone. That fact does not make exogenous insulin a casual product. Insulin is tightly regulated, requires prescription, and is among the drugs most frequently involved in serious adverse events when it is dosed incorrectly, because the difference between a physiologic concentration and a pharmacologic concentration is the difference between regulation and dysregulation.

The same general logic applies to MOTs-c, which engages AMPK and influences glucose handling. Endogenous regulation involves feedback loops, tightly bounded concentrations, and tissue-level regulation that exogenous bolus dosing does not reproduce. The fact that the body makes MOTs-c is a reasonable starting framing, but it does not itself establish that exogenous administration is safe outside of clinical trials, nor does it provide a regulatory shortcut around the standard drug-approval process.

The legal framework reflects this. The FDA’s drug-approval and compounding categories are not waived for substances that have an endogenous origin. Hormones, growth factors, and peptide signals that are made in the body still go through the same approval and compounding pathways as any other therapeutic.

The CohBar pharmaceutical history and what it tells us

CohBar Inc. is the most informative case study in any discussion of the MOTs-c regulatory bar. CohBar was a USC spinout founded specifically to translate mitochondrial-derived peptide biology into pharmaceutical candidates, with direct ties to the original research group that characterized MOTs-c in 2015.

The company explored MDP-derived analog programs and advanced candidates into early clinical evaluation in the late 2010s and early 2020s. Despite the credibility of the underlying biology, the company’s intellectual property position, and access to capital, CohBar did not bring a MOTs-c- derived therapeutic to market. The company eventually wound down operations without a commercial launch.

For a regulatory analysis, the takeaway is concrete. The standard path to making MOTs-c, or a MOTs-c analog, an FDA-approved metabolic therapy requires the same kind of formal Phase 1, Phase 2, and Phase 3 clinical trial program that any new drug requires. CohBar attempted parts of that path. The path was not completed. Until that kind of trial program is run and publicly reported, there is no shortcut by which compounded MOTs-c, even if it is being prepared by a 503A pharmacy under one interpretation of the April 2026 update, becomes a clinically validated metabolic medication. Compounding posture is a regulatory question. Clinical validity is a trial-data question, and they are not the same thing.

503A compounding implications

The legal compounding picture for MOTs-c hinges on a few specific provisions of the Federal Food, Drug, and Cosmetic Act and the FDA’s implementation of those provisions.

• Section 503A governs traditional compounding pharmacies that prepare medications based on individual patient prescriptions. PepScribe partners with 503A pharmacies exclusively, which means every dose dispensed through this platform is prescribed by a licensed clinician, prepared by a licensed compounding pharmacy, and traceable to a US-based 503A facility.
• Section 503Bcovers outsourcing facilities that can compound without individual prescriptions but must comply with current Good Manufacturing Practices (cGMP). PepScribe’s pharmacy standard is 503A-only.
• Bulk drug substance lists govern what compounders can use as starting material. MOTs-c was on the Category 2 list and was removed by the April 15, 2026 update, but it has not received Category 1 placement. Category 2 cannot be compounded by 503A pharmacies. The unambiguous green light for 503A compounding is Category 1 placement, which has not been issued for MOTs-c.

In a strict reading, the absence of Category 1 placement is the operative fact for a 503A pharmacy that wants regulatory certainty. In a more permissive reading, the removal from Category 2 plus the pending PCAC review creates room for some compounders to prepare MOTs-c on the theory that the prior prohibition has lifted. The more conservative reading is the one that supports a sustainable, low-risk operating posture for a clinical platform like PepScribe, and it is the position we hold.

Practically, this means that a patient asking PepScribe to dispense compounded MOTs-c will not be served that request. A patient asking to discuss whether any peptide therapy fits a specific metabolic goal can be served, in the form of a clinician-led consultation that considers the available formulary, including Tier 1 GLP-1-class therapies and other clinically validated tools.

Gray-market risks (with a metabolic-peptide twist)

Many of the gray-market risks that apply to research peptides in general, purity, sterility, identity, dosing accuracy, and adulteration, apply to MOTs-c just as they do to BPC-157 or TB-500. There is also a category of risk that is specific to a peptide that engages AMPK and influences glucose handling, and it is worth flagging directly.

Quality and identity risks shared with other gray-market peptides

• Purity. Without pharmaceutical-grade synthesis and quality control, gray-market MOTs-c may contain incorrect peptide sequences, truncated chains, or entirely different peptides that happen to be cheaper or easier to produce.
• Sterility.Injectable preparations carry endotoxin, bacterial, and fungal contamination risks that are particularly serious because the route of administration bypasses the body’s mucosal defenses entirely.
• Concentration accuracy. A vial labeled as containing X milligrams of MOTs-c may contain substantially more or less, with no quality-assurance testing to verify.
• Solvent and reagent residues. Uncontrolled synthesis can leave behind organic solvents, heavy metals, or reagent byproducts that appear nowhere on the label.
• No pharmacovigilance. If something goes wrong, there is no adverse-event reporting infrastructure, and the patient and clinician have no clean record of what was in the vial.

Risks specific to a metabolically active peptide

MOTs-c engages a pathway (AMPK) that is centrally involved in glucose handling and that is the same pathway targeted by metformin. That mechanism has implications for how MOTs-c could interact with diabetes medications.

• Insulin and sulfonylureas. A peptide that increases insulin sensitivity and increases skeletal-muscle glucose uptake can, in principle, lower blood glucose more than expected in a patient already on insulin or insulin-secretagogue therapy. The practical consequence of unrecognized interaction is hypoglycemia.
• Metformin. Metformin is itself an AMPK-related agent. Adding a peptide that engages the same pathway in a patient already on metformin is a clinical-judgment question, not a self-administration question.
• GLP-1 receptor agonists. Patients on semaglutide, tirzepatide, or related GLP-1-class therapies already have substantial pharmacologic engagement of glucose-handling pathways. Stacking an additional metabolically active peptide on top, without clinician oversight, is precisely the kind of thing that can produce unexpected outcomes.
• Thyroid and other endocrine contexts. Patients with thyroid disease, adrenal disease, or established metabolic syndromes have endocrine systems that interact with the same energy-regulating pathways MOTs-c engages.

The summary is that MOTs-c is not a low-stakes peptide to self-administer without medical oversight, even leaving aside the regulatory ambiguity. The possibility that the substance interacts unpredictably with diabetes medications is a specifically clinical concern, not a theoretical one.

International picture: UK, Canada, Australia, EU

The MOTs-c regulatory picture outside the United States is, broadly, stricter than the US picture. None of the major regulatory jurisdictions have approved MOTs-c as a therapeutic.

United Kingdom

MOTs-c is not licensed as a medicine by the UK Medicines and Healthcare products Regulatory Agency (MHRA). It cannot be legally marketed as a medicine or sold for therapeutic use. The UK does not have a direct analogue of the US 503A compounding pathway, and any therapeutic access would require either an MHRA-approved product or a clearly defined special-use exemption, neither of which exists for MOTs-c. Products labeled as research chemicals exist online, but those products are not regulated for human use.

Canada

Health Canada has not approved MOTs-c as either a drug or a natural health product. It is not in the Drug Product Database or the Licensed Natural Health Products Database. Provincial pharmacy regulators govern compounding in Canada, and the framework for compounding peptides without an approved product is more restrictive than the US system. Importing MOTs-c for personal use from international sources may violate the Food and Drugs Act, particularly when the product is represented as therapeutic.

Australia

Australia’s Therapeutic Goods Administration (TGA) is among the strictest regulators for peptides globally. MOTs-c is not on the Australian Register of Therapeutic Goods (ARTG). The TGA has actively targeted the importation and sale of unapproved peptides, and Australian Border Force has seized peptide shipments at the border. Compounding pharmacies in Australia generally cannot prepare substances that are not TGA-approved without a specific exemption.

European Union

MOTs-c is not approved by the European Medicines Agency (EMA) and is not authorized for therapeutic use in any EU member state. EU pharmaceutical regulation generally requires either a centralized EMA authorization or a national-level authorization for a marketed product, neither of which exists for MOTs-c. Member states have varying approaches to compounding, but the absence of an approved product places MOTs-c outside the standard therapeutic-access framework EU-wide.

International takeaway

No major regulatory authority has approved MOTs-c for therapeutic use. The US picture, with its post-April-2026 regulatory ambiguity, is somewhat less restrictive than the EU, UK, Canadian, and Australian pictures, but it is still not a green-light environment.

WADA and sport status

The World Anti-Doping Agency (WADA) maintains a Prohibited List of substances banned in sport. The list is reviewed and updated annually, and it includes broad categories such as peptide hormones, growth factors, related substances, and metabolic modulators, in addition to substances named explicitly.

MOTs-c has attracted WADA-adjacent interest precisely because of the exercise-mimetic framing in the scientific literature: a peptide that engages AMPK, increases skeletal-muscle glucose uptake, and shifts substrate use toward fatty acid oxidation overlaps with classes of agents that are already restricted in competitive sport. Based on public information at the time of writing, MOTs-c does not appear by name on the most recent Prohibited List, but the WADA framework includes a catch-all provision (S0) that prohibits substances which are not approved by any governmental regulatory health authority for human therapeutic use, when used by an athlete in competition.

That catch-all is directly relevant to MOTs-c. Because MOTs-c is not approved for human therapeutic use anywhere, an athlete subject to WADA jurisdiction who used MOTs-c could face consequences under S0 even in the absence of explicit named-substance listing. Competitive athletes should consult the current WADA Prohibited List directly and their sport’s anti-doping authority before considering any peptide, and they should treat MOTs-c as high-risk in this context.

Detection methodology is also evolving. Anti-doping laboratories have developed mass-spectrometry-based methods for synthetic peptides, and the absence of a positive test today does not guarantee future undetectability.

Possession vs sale: a critical distinction

Three different legal questions tend to get collapsed in conversations about peptide legality, and they are worth separating.

1. Is possession criminalized? In the United States, MOTs-c is not a controlled substance. Possessing MOTs-c for personal use is unlikely to expose a person to criminal controlled-substance penalties. This is a different question from whether it is legal to sell, prescribe, or self-administer.
2. Is sale for human use lawful? Selling MOTs-c for human consumption, in a way that holds it out as a therapeutic product, is not consistent with current FDA regulations. Vendors who do this often hide behind “for research use only” labels, which do not provide the legal protection their language suggests when context indicates the product is intended for human use.
3. Is prescription dispensing lawful? Under a strict reading of the post-April-2026 status, 503A compounding of MOTs-c does not have unambiguous Category 1 backing. PepScribe takes the conservative position and does not dispense MOTs-c.

None of these answers translate into “MOTs-c is legal to use, freely available, and clinically validated.” The honest summary is more nuanced: not criminalized, not approved, in a regulatory ambiguity for compounding, and unsupported by the kind of human trial data that would make it a validated metabolic therapy.

What reclassification would require

Patients and clinicians sometimes ask what it would take for MOTs-c to move from its current ambiguous posture into a clearly approved therapeutic position. The honest answer is the standard drug-development path. There is no regulatory side door for an interesting endogenous peptide.

• Phase 1 trials. Small, carefully monitored studies in healthy volunteers establish basic safety, tolerability, dosing range, and preliminary pharmacokinetics. CohBar attempted aspects of this kind of work for MDP-derived candidates without carrying a MOTs-c product to market.
• Phase 2 trials. Larger studies in patients with the target condition (for example, type 2 diabetes, obesity, or a metabolic-syndrome population) establish preliminary efficacy and refine the dosing regimen.
• Phase 3 trials. Large randomized controlled trials with clinical endpoints (such as A1c reduction, weight change, cardiovascular outcomes) generate the pivotal evidence required for approval.
• FDA new drug application. A formal NDA with the trial data, manufacturing standards, labeling, and risk-management plan goes to the FDA for review.
• Post-approval pharmacovigilance. An approved product carries ongoing safety monitoring obligations and potential post-marketing studies.

Alternatively, a Category 1 placement on the bulk drug substance lists following PCAC review could open a clearer 503A compounding pathway without a fully approved branded product, but only with the FDA’s affirmative evaluation of identity, purity, characterization, and safety. Neither path has been completed, and both are measured in years, not months.

Currently available metabolic alternatives: semaglutide and tirzepatide

For patients whose actual interest is metabolic health, weight regulation, or insulin sensitivity, the framing that matters is not “is MOTs-c legal” but “what metabolic peptides have a credible regulatory posture and a substantial human evidence base today.” The two clearest answers in 2026 are semaglutide and tirzepatide.

Semaglutide

Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist with extensive randomized human clinical trial data for type 2 diabetes and for weight regulation in adults with obesity or overweight with weight-related comorbidities. The reference branded products (Ozempic for diabetes, Wegovy for weight management) are FDA-approved, which places the molecule itself in the Category 1 universe. Compounded semaglutide has been clinically available through licensed compounding pharmacies under shortage-period rules, with prescriber oversight.

For most patients exploring metabolic peptides for weight or glycemic support, semaglutide is the more legitimate metabolic-peptide path. It has the trial base, it has the regulatory posture, and it is dispensed from a US 503A compounding pharmacy with a licensed clinician as prescriber.

Tirzepatide

Tirzepatide is a dual GIP and GLP-1 receptor agonist with strong randomized human clinical trial data, particularly for weight regulation and glycemic control. The reference branded products (Mounjaro for diabetes, Zepbound for weight management) are FDA-approved. The dual-agonist mechanism produces, on average, larger glycemic and weight-related effects than single-agonist GLP-1 therapy in head-to-head studies.

Tirzepatide is the second clearly legitimate metabolic-peptide pathway under current US rules, and for many patients it is the option a clinician will discuss alongside semaglutide.

Why these are the legitimate path

The reason semaglutide and tirzepatide belong in this article is not marketing. It is that these molecules answer the underlying question that most MOTs-c-curious patients are trying to answer. If your concern is insulin sensitivity, weight regulation, glucose handling, or metabolic health more broadly, the highest-yield clinical conversation in 2026 is about GLP-1-class therapy, not about a research peptide whose human evidence base is observational, whose regulatory posture is ambiguous, and whose clinical translation attempt by an experienced spinout did not result in a marketed product.

MOTs-c may yet have a clinical role, particularly if the kind of trial program CohBar attempted is eventually completed by a future sponsor. Until that happens, the clinical and regulatory choice in metabolic peptide therapy is between research peptide framing on the one hand, and evidence-based GLP-1 receptor agonist therapy on the other. For nearly all patients, that choice is straightforward.

Practical takeaways

• MOTs-c is in a regulatory gray zone following the April 15, 2026 update: removed from explicit Category 2, not placed on Category 1, pending PCAC review.
• PepScribe’s pharmacy standard is 503A-only, and PepScribe does not dispense MOTs-c. MOTs-c is consultation-first, not a peptide-direct product.
• Endogenous origin is not a shortcut. The body making MOTs-c does not exempt exogenous administration from the standard regulatory and clinical-validation path.
• CohBar attempted the legitimate path and did not bring a MOTs-c product to market. That is the most informative case study in any analysis of the regulatory bar.
• Gray-market MOTs-c carries serious risks, including the metabolic-peptide-specific risk of unrecognized interaction with diabetes medications.
• Internationally, no major regulator has approved MOTs-c. The US regulatory ambiguity is the most permissive of the major jurisdictions, and it is still not a green-light environment.
• For metabolic-health goals, semaglutide at /peptides/semaglutide and tirzepatide at /peptides/tirzepatide are the legitimate metabolic-peptide options under current US rules. They have the human trial base, the regulatory posture, and the clinical pathway that MOTs-c does not yet have.